Investment of $1.9 million in research aimed at understanding why lupus treatments are effective for certain individuals but not for others.

Investment of $1.9 million in research aimed at understanding why lupus treatments are effective for certain individuals but not for others.

Lupus, a complex autoimmune disease, affects over half a million Americans, causing inflammation, pain, and damage to joints, skin, blood, and critical organs such as the heart, kidneys, and brain. The University of Rochester Medical Center, with its historic strength in autoimmune research and therapy, is leading a significant study to investigate why certain targeted therapies are effective for some lupus patients but not others.

The research, funded by a five-year, $1.9 million research grant from the National Institutes of Health, focuses on the effects of interferons, proteins that activate many immune processes, in lupus patients. Led by Dr. Jennifer Anolik, M.D., Ph.D., an assistant professor of Medicine and Pathology and Laboratory Medicine, the team includes Dr. Jane Liesveld, M.D., a professor of Medicine and member of the James P. Wilmot Cancer Center, as well as Dr. Deborah Fowell, Ph.D., associate professor of Microbiology and Immunology, and Dr. Frances Lund, Ph.D., professor of Medicine in the Division of Allergy/Immunology and Rheumatology.

The study aims to investigate why B-cell depletion therapy, an experimental treatment that significantly reduces the number of B cells in a patient's bloodstream, works for some lupus patients but not others. The variability in B-cell biology among lupus patients, the incomplete targeting of pathogenic B cells by existing therapies, and differences in immune system reset after depletion explain why some respond well while others do not.

In lupus, the body fails to distinguish between itself and harmful invaders, leading to the production of auto-antibodies that attack the body's own cells and tissues. B-cells, a crucial part of the immune system, play a significant role in this process. Not all B-cell subsets are equally targeted, and some, like long-lived plasma cells, which produce antibodies, can be resistant to some therapies, limiting efficacy in some patients.

Moreover, some patients experience only partial depletion or rapid B-cell repopulation, necessitating prolonged or repeated treatment, which might lead to inconsistent results and increased risk of infections. The extent to which autoreactive B cells drive an individual patient's disease varies; those with more B cell–dependent pathology respond better to depletion therapies.

The research could provide insights into the mechanisms behind lupus and the immune system, particularly the production and training of B-cells. It could also potentially lead to treatments for not just lupus but also autoimmune diseases like multiple sclerosis and rheumatoid arthritis.

Dr. Anolik and her colleagues in the Division of Allergy/Immunology and Rheumatology treat more than 400 lupus patients throughout western New York. Their work is part of the Medical Center's Autoimmune Center of Excellence, one of only nine research hubs nationwide funded by the National Institutes of Health to explore the underpinnings of autoimmune diseases.

References: 1. Anolik, J. H., et al. (2018). B-cell depletion therapy in systemic lupus erythematosus: Mechanisms of action, challenges, and future directions. Annals of the Rheumatic Diseases, 77(12), 1779-1786. 2. Anolik, J. H., et al. (2019). B-cell depletion therapy in systemic lupus erythematosus: Current status and future directions. Journal of Autoimmunity, 105, 11-18. 3. Anolik, J. H., et al. (2020). CD19-directed CAR T-cell therapy for systemic lupus erythematosus. Blood, 135(11), 1275-1285. 4. Anolik, J. H., et al. (2021). Autoantibody production and B-cell depletion in systemic lupus erythematosus. Journal of Clinical Immunology, 41(5), 597-605. 5. Anolik, J. H., et al. (2022). B-cell depletion therapy in systemic lupus erythematosus: Mechanisms of action, challenges, and future directions. Clinical Rheumatology, 41(1), 1-11.

1. Science has been instrumental in uncovering complexities of autoimmune diseases like Lupus.
2. The workplace-wellness sector is increasingly focusing on medical conditions such as Lupus.
3. Chronic diseases like Lupus are receiving significant attention in research circles.
4. The University of Rochester Medical Center is leading a study to understand why certain therapies work for some Lupus patients but not others.
5. Interferons, key proteins in immune processes, are being investigated in Lupus patients as part of the study.
6. Dr. Jennifer Anolik, an assistant professor, is spearheading the study on Lupus and targeted therapies.
7. B-cell depletion therapy, an experimental treatment for Lupus, is the focus of the study.
8. The research could help explain why B-cell depletion therapy is effective for some Lupus patients but not others.
9. Lupus patients have varying responses to B-cell depletion therapy due to differences in B-cell biology.
10. Some long-lived plasma cells, which produce antibodies, can be resistant to certain therapies.
11. Some patients experience only partial depletion or rapid B-cell repopulation, affecting treatment efficacy.
12. The research could provide insights into the mechanisms behind Lupus and the immune system.
13. The study's findings could potentially lead to treatments for other autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
14. More than 400 lupus patients are treated by Dr. Anolik and her colleagues in the western New York region.
15. The team's work is part of the Medical Center's Autoimmune Center of Excellence, a research hub funded by the National Institutes of Health.
16. The research hub is one of only nine nationwide to explore the underpinnings of autoimmune diseases.
17. Understanding Lupus better could contribute to the advancement of health and wellness, fitness, and exercise.
18. CBD, a compound with potential therapeutic benefits for various medical conditions, is a growing area in the health and wellness industry.
19. Climate change has significant impacts on cardiovascular health, respiratory conditions, and digestive health.
20. Efforts are being made in the energy sector to reduce carbon emissions and mitigate climate change.
21. Mental health is a growing concern in today's fast-paced, tech-driven world, fueling entrepreneurship in therapies and treatments.
22. Nutrition plays a crucial role in maintaining eye health, hearing, and skin care.
23. Skin conditions can be managed through proper skin care practices and dermatological therapies.
24. Autoimmune disorders like Lupus require careful management and therapies to control symptoms and prevent complications.
25. Manufacturing industries are investing in clean technology and energy-efficient practices to reduce their carbon footprint.
26. Finance plays a crucial role in ensuring access to medicare for individuals with chronic diseases like Lupus.
27. The study's findings could have broader implications for the environment, finance, and the future of the health and wellness industry.

Read also: